Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | BTK | Q06187 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.39 |
| ▸ | DLK1 | P80370 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493446 | 0.86 | SYK (0.54) | PHGDHUSP30RIOK2SYKALDH1A1 | |
| SCHEMBL3494267 | 0.85 | HIF1A (0.47) | — | |
| SCHEMBL3493084 | 0.83 | RIOK2 (0.43) | PHGDHUSP30RIOK2NR3C2SYK | |
| SCHEMBL3493858 | 0.81 | USP30 (0.48) | PHGDHUSP30RIOK2BTKMAP3K12 | |
| SCHEMBL3491790 | 0.79 | AKT2 (0.56) | — | |
| SCHEMBL13369028 | 0.77 | AKT1S1 (0.49) | PHGDHUSP30MAP3K12 | |
| SCHEMBL3495308 | 0.77 | NAMPT (0.39) | — | |
| SCHEMBL3490712 | 0.75 | TRPV1 (0.44) | USP30 | |
| SCHEMBL3494822 | 0.74 | RAB9A (0.47) | ALDH1A1GAAL3MBTL1 | |
| SCHEMBL3495082 | 0.74 | L3MBTL1 (0.47) | ALDH1A1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2125820-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | PHGDH 1482/4885USP30 3989/4885RIOK2 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.